The Kanabo share price is surging! Time to buy?

After months of lacklustre performance, the Kanabo share price is finally on the rise. Zaven Boyrazian investigates what’s behind this growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

After months of idle and lacklustre performance, the Kanabo (LSE:KNB) share price is finally on the rise. In fact, over the last couple of weeks, the medical cannabis stock is up by nearly 80%! What’s behind this new-found growth? And is it time to adding this company to my portfolio? Let’s take a look.

The rising Kanabo share price

Since the last time I looked at this business, quite a few developments have taken place. As a quick reminder, Kanabo develops and manufactures cannabidiol-based products (like oils) for the health & wellness sector. It combines the sale of these oils with its proprietary inhalation device, VapePod, effectively creating a Gillette-style razor & blade business model. If successful, I think Kanabo’s share price could see some considerable growth.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Last month, the company announced the shipment of its first medicinal cannabis cartridges to the UK. These were produced with the help of its partner PharmaCann Polska. And thanks to the partnership with Astral Health, access to patients in need of such a product has been relatively straightforward.

Moreover, because doctors can prescribe specific doses with the VapePod devices (something not possible with the traditional smoking approach), Kanabo’s product seems to have several advantages for medicinal purposes. But besides revenue finally coming in, this successful product launch also proves that its supply and production pipeline works. So, I’m not surprised to see Kananbo’s share price rising on the news.

More growth comes with more risk

Now that a customer base has been established, the management team wants to act rapidly through strategic acquisitions. Towards the end of July, the company proposed acquiring the European firm, Materia. Besides having a Good Manufacturing Practice (GMP) certification, Materia owns a licensed medical cannabis wholesaler in Germany. By purchasing the business, Kanabo would gain access to an already established network of pharmacies as a new sales channel.

That certainly sounds like a good move. However, acquisitive growth strategies have their risks. Firstly, the management team intends to sell additional Kanabo shares to fund the proposed deal since the lack of profitability makes debt financing unsuitable. That will lead to a potentially significant amount of equity dilution, pushing Kanabo’s share price down.

What’s more, there is no guarantee this deal will be successful. Integrating a company into another often leads to complications that can destroy value rather than create it. With Kanabo’s limited history and experience performing acquisitions, the risk of integration pains seems high, in my opinion.

The Kanabo share price has its risks

The bottom line

Since its IPO last February, Kanabo has been slowly turning into what looks like a viable business. The partnerships formed in the past few months have already started to bear fruit. And with certification being received for its products, it seems the company has managed to overcome the initial challenges it faced. That’s encouraging news for Kanabo’s share price.

Having said that, I’m still on the fence as to whether this is a business worth owning. On an operational level, it looks like it’s in a solid position. However, there remains an aura of mystery surrounding its financials. With limited information about its most recent sales volume and price, Kanabo remains difficult to judge, in my mind. Therefore, I’m keeping it on my watchlist for now.

Instead, I'm far more tempted by another recent IPO stock

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

Best British dividend stocks for July

We asked our freelance writers to share the top income stocks they’d buy in July, which included Dividend Aristocrats and…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

How I’d apply the Warren Buffett method to buying shares

Learning from billionaire investor Warren Buffett, our writer explains his own approach to investing in shares for his portfolio.

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

This dividend share yields under 1% — but I’d still buy it

This dividend share has a low yield. So why would our writer consider adding it to his income portfolio?

Read more »

Young lady working from home office during coronavirus pandemic.
Investing Articles

Looking for a good share to buy? Here’s how I do it

Here are two approaches our writer uses when hunting for a good share to buy for his portfolio to aim…

Read more »

man in shirt using computer and smiling while working in the office
Investing Articles

One cheap FTSE 100 share I’d buy for a new bull market

This FTSE 100 share is unloved and starting to look seriously cheap, says Roland Head.

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

How I’d invest £500 in UK shares in 2022

Investing a small amount of capital in UK shares can result in high commission costs. Zaven Boyrazian explains how to…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

2 battered FTSE dividend stocks to buy in July!

I'm still searching the FTSE 100 for the best bargains to buy. I think these two big dividend shares are…

Read more »

Woman pulling baffled face
Investing Articles

Can I trust Lloyds’ 6.1% dividend yield?

The Lloyds' share price has sunk in 2022, causing the bank's dividend yield to leap. But can I really trust…

Read more »